EUVIMEDEUVIMED entdecken
Crossref

Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions

Kaspar Rufibach iD, Lynda Grinsted, Jiang Li, Hans Jochen Weber iD, Cheng Zheng, Jiangxiu Zhou

Pharmaceutical Statistics · 2023

DOI: 10.1002/pst.2300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2023. Verfasst von Kaspar Rufibach und 5 weiteren Autor:innen. Beteiligte Einrichtung: Methods, Collaboration, and Outreach Group (MCO), Product Development Data Sciences, Hoffmann-La Roche Ltd, Basel, Switzerland. Hauptthemen laut MEDLINE: Research Design, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For the analysis of a time‐to‐event endpoint in a single‐arm or randomized clinical trial it is generally perceived that interpretation of a given estimate of the survival function, or the comparison between two groups, hinges on some quantification of the amount of follow‐up. Typically, a median of some loosely defined quantity is reported. However, whatever median is reported, is typically not answering the question(s) trialists actually have in terms of follow‐up quantification. In this paper, inspired by the estimand framework, we formulate a comprehensive list of relevant scientific questions that trialists have when reporting time‐to‐event data. We illustrate how these questions should be answered, and that reference to an unclearly defined follow‐up quantity is not needed at all. In drug development, key decisions are made based on randomized controlled trials, and we therefore also discuss relevant scientific questions not only when looking at a time‐to‐event endpoint in one group, but also for comparisons. We find that different thinking about some of the relevant scientific questions around follow‐up is required depending on whether a proportional hazards assumption can be made or other patterns of survival functions are anticipated, for example, delayed separation, crossing survival functions, or the potential for cure. We conclude the paper with practical recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignNeoplasmsHumansFollow-Up StudiesMedical OncologyTime FactorsRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

estimandfollow-up timerandomized trialtime-to-event

Autor:innen und Institutionen

  • Methods, Collaboration, and Outreach Group (MCO), Product Development Data Sciences, Hoffmann-La Roche Ltd, Basel, Switzerland.
  • AstraZeneca UK Ltd, Cambridge, Cambridgeshire, UK.
  • BeiGene USA, Inc., 55 Challenger Road, Ridgefield Park, New Jersey, 07660, USA.
  • Clinical Development and Analytics, Novartis Pharma AG, Basel, Switzerland.
  • Zentalis Pharmaceuticals, New York, New York, USA.
  • Statistics and Decision Sciences, J&J, Spring House, Pennsylvania, USA.

ORCID-Profile: Kaspar Rufibach, Hans Jochen Weber

Zitieren

APA

Rufibach, K., Grinsted, L., Li, J., Weber, H. J., Zheng, C., & Zhou, J. (2023). Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2300

Vancouver

Rufibach K, Grinsted L, Li J, Weber HJ, Zheng C, Zhou J. Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions. Pharmaceutical Statistics. 2023. doi:10.1002/pst.2300

BibTeX
@article{Rufibach2023,
  author = {Rufibach, Kaspar and Grinsted, Lynda and Li, Jiang and Weber, Hans Jochen and Zheng, Cheng and Zhou, Jiangxiu},
  title = {Quantification of follow‐up time in oncology clinical trials with a time‐to‐event endpoint: Asking the right questions},
  journal = {Pharmaceutical Statistics},
  year = {2023},
  doi = {10.1002/pst.2300}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche